Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.

In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Related Content
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

April 23rd 2024
Article

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma

Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma

April 17th 2024
Article

The recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates

February 19th 2024
Podcast

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Rectal Cancer Surgical Outcomes Improved at Accredited Hospitals

Rectal Cancer Surgical Outcomes Improved at Accredited Hospitals

April 9th 2024
Article

In-hospital mortality and complication rates were lower at accredited hospitals vs those not accredited for patients undergoing rectal cancer surgery.